Technical Analysis for TCRR - TCR2 Therapeutics Inc.

Grade Last Price % Change Price Change
F 19.01 -1.45% -0.28
TCRR closed down 1.45 percent on Thursday, May 13, 2021, on 66 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical TCRR trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup -1.45%
Lower Bollinger Band Walk Weakness -1.45%
Wide Bands Range Expansion -1.45%
Oversold Stochastic Weakness -1.45%
Lower Bollinger Band Walk Weakness -1.71%
Wide Bands Range Expansion -1.71%
Lower Bollinger Band Touch Weakness -1.71%
Older End-of-Day Signals for TCRR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Lower Bollinger Band Support about 8 hours ago
Down 3% about 9 hours ago
Slingshot Bearish Entry about 9 hours ago
Fell Below Previous Day's Low about 9 hours ago
Down 2 % about 9 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

TCR2 Therapeutics Inc. Description

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Immunotherapy Lymphoma Cancer Immunotherapy Small Cell Lung Cancer Non Small Cell Lung Cancer Ovarian Cancer Carcinoma Proteins Acute Lymphoblastic Leukemia Helio Hematological Malignancies Treatment Of Non Small Cell Lung Cancer CD19 Nsclc Tumors Of The Hematopoietic And Lymphoid Tissues Immunogen Mesothelioma Mesothelin Cholangiocarcinoma Diffuse Large B Cell Lymphoma Positive Solid Tumors

Is TCRR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.86
52 Week Low 9.325
Average Volume 490,673
200-Day Moving Average 23.92
50-Day Moving Average 23.05
20-Day Moving Average 22.16
10-Day Moving Average 20.49
Average True Range 1.36
ADX 26.37
+DI 10.26
-DI 32.10
Chandelier Exit (Long, 3 ATRs ) 21.01
Chandelier Exit (Short, 3 ATRs ) 22.14
Upper Bollinger Band 26.08
Lower Bollinger Band 18.24
Percent B (%b) 0.1
BandWidth 35.38
MACD Line -1.17
MACD Signal Line -0.78
MACD Histogram -0.3833
Fundamentals Value
Market Cap 635.35 Million
Num Shares 33.4 Million
EPS -10.67
Price-to-Earnings (P/E) Ratio -1.78
Price-to-Sales 0.00
Price-to-Book 3.84
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.99
Resistance 3 (R3) 21.00 20.36 20.66
Resistance 2 (R2) 20.36 19.85 20.35 20.55
Resistance 1 (R1) 19.68 19.54 19.36 19.67 20.44
Pivot Point 19.04 19.04 18.88 19.03 19.04
Support 1 (S1) 18.36 18.53 18.04 18.35 17.58
Support 2 (S2) 17.72 18.22 17.71 17.47
Support 3 (S3) 17.04 17.72 17.36
Support 4 (S4) 17.03